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Background: The recent emergence and spread of artemisinin resistance in the Greater Mekong Subregion poses a
great threat to malaria control and elimination. A K13-propeller gene (K13), PF3D7_1343700, has been associated
lately with artemisinin resistance both in vitro and in vivo. This study aimed to investigate the K13 polymorphisms in
Plasmodium falciparum parasites from the China-Myanmar border area where artemisinin use has the longest history.
Methods: A total of 180 archived P. falciparum isolates containing 191 parasite clones, mainly collected in 2007–2012
from the China-Myanmar area, were used to obtain the full-length K13 gene sequences.
Results: Seventeen point mutations were identified in 46.1% (88/191) parasite clones, of which seven were new.
The F446I mutation predominated in 27.2% of the parasite clones. The C580Y mutation that is correlated with
artemisinin resistance was detected at a low frequency of 1.6%. Collectively, 43.1% of the parasite clones contained
point mutations in the kelch domain of the K13 gene. Moreover, there was a trend of increase in the frequency of
parasites carrying kelch domain mutations through the years of sample collection. In addition, a microsatellite
variation in the N-terminus of the K13 protein was found to have reached a high frequency (69.1%).
Conclusions: This study documented the presence of mutations in the K13 gene in parasite populations from the
China-Myanmar border. Mutations present in the kelch domain have become prevalent (>40%). A predominant
mutation F446I and a prevalent microsatellite variation in the N-terminus were identified, but their importance in
artemisinin resistance remains to be elucidated.
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Malaria has been scourging human beings for millennia,
and remains responsible for over 430,000 child deaths in
Africa every year [1]. The world has made remarkable
strides in battling against this ancient enemy during the
past decade, reducing by an impressive 47% in mortality
rate globally between 2000 and 2013 [1]. However, parasite
resistance to anti-malarials remains an ever-present obs-
tacle to eliminate malaria. Chloroquine and sulphadoxine-
pyrimethamine have failed as crucial medicines in the
treatment of the deadly malaria parasite Plasmodium* Correspondence: luc2@psu.edu
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unless otherwise stated.falciparum due to the emergence and rapid spread of drug
resistance. More worryingly, resistance to artemisinin
(ART) family drugs has been detected and is spreading
in Southeast Asia [2-4], posing a major threat to the im-
plementation of artemisinin-based combination therapy
(ACT) as a defensive line against P. falciparum.
ART resistance is manifested clinically as delayed para-
site clearance half-life (>5 hours) in vivo [4,5]. An in vitro
ring-stage survival assay (RSA0-3h), which measures the
percentage of early ring-stage parasites (0–3 hrs post-
invasion of red blood cells (RBCs)) that survive exposure
to a pharmacologically relevant concentration of dihy-
droartemisinin, has been developed to reflect this ART re-
sistance phenotype [6]. Recent work has associated ART
resistance with mutations in the propeller domain of aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gene) [5]. The K13 mutation M476I was initially identified
in a Tanzanian P. falciparum strain that had undergone
in vitro ART selection for five years. Research on parasite
isolates from Cambodia, where ART resistance was first
observed, identified K13 mutations Y493H, R539T and
C580Y to be associated with delayed clearance [5]. These
mutations were confirmed to contribute to in vitro ART
resistance through genetic manipulations of the K13 gene
[7,8]. A large, multicentre, clinical study further indicates
that ART resistance is spreading in the Greater Mekong
Subregion (GMS), where single-point mutations in the
propeller domain of K13 after the position 440 are collect-
ively associated with ART resistance [4]. Surveys con-
ducted in different regions showed that K13 mutations
associated with ART resistance were restricted to cer-
tain areas of the GMS, including Cambodia, Thailand,
Myanmar, and Vietnam. The C580Y mutation is the pre-
dominant one approaching fixation in Western Cambodia
[5,9-11]. These mutations have not been detected in
Bangladesh and Laos [4,10,12]. Surveys of African parasite
populations, while having found a diverse array of muta-
tions within the K13 gene, did not detect those mutations
associated with ART resistance [13-17].
ART family drugs have been used in China’s Yunnan
Province since the late 1970s [18]. In recent years, clin-
ical efficacy studies conducted in this region showed that
artemisinin drugs for treating falciparum malaria remain
highly effective [19,20]. However, the proportion of day
3 parasite-positive cases in one study reached 18.5% [20],
well above the 10% threshold set by the World Health
Organization as a proxy indicator of suspected ART resist-
ance [21], suggesting possible emergence of ART resist-
ance in this area. In this study, the polymorphisms of K13
genes in parasite populations along the China-Myanmar
border were investigated, and the presence of K13 mu-
tations that are associated with clinical ART resistance
in this region was demonstrated using longitudinally
archived parasite samples. More importantly, parasite
strains carrying wild-type K13 alleles have been declin-
ing through the six years of sample collection.
Methods
Collection of parasite clinical isolates, DNA extraction and
genotyping
Plasmodium falciparum clinical isolates were collected
during the period 2004–2012 in malaria clinics located
along the China-Myanmar border, cultured and archived
[22]. A total of 180 samples were analysed including two
collected in 2004, 25 in 2007, 47 in 2008, 78 in 2009, 11
in 2010, five in 2011, and 12 in 2012. Genomic DNA
was extracted using the Wizard® Genomic DNA Purifi-
cation Kit (Promega, WI, USA). Parasite samples were
genotyped at msp1, msp2 and glurp using previouslydescribed methods [23-25] to distinguish single from
mixed-strain infections [26].
K13 propeller gene amplification and sequencing analysis
The full-length K13 gene was amplified by high-fidelity
PCR using Advantage HD DNA Polymerase Mix
(Clontech, Mountain View, CA, USA) and primers
KP13-F (5′-TATAACAAGGCGTAAATATTCGTG-3′)
and KP13-R (5′-TGTGCATGAAAATAAATATTAAAG
AAG-3′). PCR reactions were performed in 37.5 μl with
0.5 μM of DNA template, 0.2 μM of each primer,
3.75 μl of 10 × PCR buffer, 3.75 units of DNA polymer-
ase mix, and 0.2 mM of dNTP mix. Reaction conditions
consisted of an initial denaturation at 95°C for 5 min
followed by 35 cycles of 95°C for 30 sec, 55°C for 30 sec
and 68°C for 3 min, and a final extension step for 7 min at
68°C. PCR products were sequenced in both directions
using sequencing primers KP13-65 F (5′-GGGAATCT
GGTGGTAACAGC-3′), KP13-640R (5′-CACTAGCAT
CACTTAATTCCGTT-3′), KP13-517 F (5′-GATGCAG
CAAATCTTATAAATGATG-3′), KP13-759 F (5′-GGAA
AGAGTACGATTGTACAAAG-3′), KP13-1363R (5′-CT
ACACCATCAAATCCACCTATA-3′), KP13-1595 F (5′-
GTGGTGTTACGTCAAATGGTAG-3′), and KP13-R.
Sequences were assembled by DNASTAR (WI, USA)
with manual editing. Alignment of DNA sequences were
performed using MEGA 6.0 [27] with the K13 sequence
of the 3D7 clone (PF3D7_1343700) retrieved from Plas-
moDB as the reference. To superimpose the mutations
in the K13 protein, the 3D structure of the K13 protein
was predicted by Phre2 online protein structure predic-
tion tool [28]. The chosen template retained 100%
confidence based on homology assessment and model
prediction quality.
Statistical analysis
Fisher’s exact test was done to assess difference in the
frequency of mutations between years using GraphPad
Prism 5 (GraphPad Software, Inc. La Jolla, CA, USA).
Results
The full-length K13-propeller genes were sequenced
from a total of 180 clinical isolates collected from mal-
aria patients along the China-Myanmar border. Of these
isolates, 178 were collected during 2007–2012, while two
were collected in 2004. Genotyping of these parasites at
three polymorphic genes confirmed that 169 were mono-
clonal infections, whereas 11 were mixed infections at one
of the three loci [29]. Since each of the mixed infections
contained only two allelic types, they were considered as
having two parasite strains in each sample. Based on their
clear sequencing chromatograms, these mixed infections
were also included in the analysis. Accordingly, the
Figure 1 Prevalence of K13 mutations in parasites collected from
the China-Myanmar border area in 2007–2012.
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parasite clones in the study population.
Sequencing of the K13 genes in the 191 clones revealed
that 88 (46.1%) contained single nucleotide polymor-
phisms (SNPs) at 17 locations. All 17 SNPs were non-
synonymous; no synonymous mutation was detected in
these isolates. In addition, variations in the number of a
microsatellite repeat (ATA) corresponding to amino acid
positions 137–142 of K13 in 3D7 parasite were also ob-
served. This microsatellite sequence encodes the Asn (N)
residue and is present in 30.4, 69.1 and 0.5% of the 191
clones as six (wild type), eight and nine Ns, respectively.
For the point mutations, ten (K189T, E252Q, R255K,
P441L, F446I, N458Y, P574L, C580Y, A676D and H719N)
were described previously [4,5,30,31] and seven (N11Y,
I352T, I376V, P443S, C469Y, L492S and F495L) were new
to parasites in this region (Table 1, Figure 1). All of these
mutations occurred singly, except that a double-mutation
P574L and F446I was detected in one parasite clone. One
major distinction of this parasite population is the pre-
dominant status of the F446I substitution, reaching a
frequency of 27.2%. Coincidently, this point mutation was
only observed in parasites with the 8 N repeats at the
microsatellite locus. The P574L mutation was the second
most prevalent (6.7%). The rest of mutations were all rare
and occurred in one to three clones (0.5–1.6%). It isTable 1 Amino acid substitutions in the K13 gene in



















In kelch domain 79 (41.3)
Total 88 (46.1)
*indicates unique mutations identified in this parasite population. Letters in
bold indicate mutated amino acids.noteworthy that the C580Y mutation, which was corre-
lated with ART resistance and prevailed in other areas of
Southeast Asia, was present in only three clones (1.6%).
None of the I543T, R539T and Y493H mutations associ-
ated with delayed parasite clearance in the Cambodian
isolates, or the M476I substitution selected in vitro in a
Tanzanian strain, was observed in this parasite population.
The K13 protein contains a piece of Plasmodium-spe-
cific sequence and a BTB/POZ domain in the N-terminus,
and a 6-blade propeller domain in the C-terminus (codons
441–725) [5]. Of the 17 mutations identified in this para-
site population, six were distributed in the N-terminus in
nine clones, whereas the remaining 11 occurred within
the kelch propeller domain in 41.3% parasite clones.
Superimposing the mutations to the predicted kelch do-
main structure showed that five (P441L, P443S, F446I,
N458Y, C469Y) were clustered in blade I, two (L492S and
F495L) in blade II, two (P574L and C580Y) in blade IV,
and two (A676D and H719N) in blade VI (Figure 2). A re-
cent multicentre clinical investigation showed that various
mutations occurring in the kelch domain after position
440 are collectively associated with an increase in parasite
clearance half-life [4]. When the samples were stratified
by the year of collection, the frequencies of all mutations
in the kelch domain, as well as all mutations in K13 gene,
increased during the time 2007–2012 (Figure 3). In par-
ticular, a significant increase was observed in the frequen-
cies of mutations in the kelch domain between 2008 and
2009 (P <0.0001). However, the frequencies of mutations
in the N-terminus of K13 protein decreased over the years
of collection (Figure 3).
Discussion
The involvement of K13 mutations in ART resistance in
Cambodia encouraged molecular surveillance of K13
Figure 2 Distribution of the mutations in the predicted 3D model of the K13 propeller domain. The predicted structure of the propeller domain
forms six propeller blades that contain predominantly strands. The locations of the various mutations are indicated by spheres, where red colour
represents new mutations, orange for previous reported mutations, and pink for mutations correlated with ART resistance reported by Ariey et al.
The relative frequencies of the mutations are reflected by the size of the spheres.
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associated with ART resistance were mainly detected in
areas of the GMS [5,9-11], with C580Y being the pre-
dominant. In contrast, surveys in Africa identified nu-
merous mutations in the K13 gene, but most occurred at
low frequencies. Moreover, mutations associated with
ART resistance were not observed [13-16]. In this study,
sequencing of K13 gene from 180 longitudinally collected
parasite samples (containing 191 parasite clones) from the
China-Myanmar border area identified 17 mutations (ten
previously described and seven new). Compared with
other surveys in Myanmar or the China-Myanmar border,Figure 3 Frequencies of K13 mutations in 2007 to 2012. Significant
increase in frequencies of mutations in the kelch domain in 2009
was noted.parasites from this study shared three mutations (F446I,
P574L and A676D) with those reported by Feng et al.
[30], three (P441L, N458Y and C580Y) with those re-
ported by Nyunt et al. [9] and four (F446I, P574L,
C580Yand A676D) with those reported by Tun et al.
[31]. Of particular interest is the identification of the
F446I as the predominant mutation in the study sam-
ples, which has reached a frequency of 27.1%, coincident
with results from other study (19.2%) in this region [30].
Although other mutations were at low frequencies, they
collectively gave a total of 41.3% parasites carrying mu-
tations in the kelch domain. Among them, the predom-
inant C580Y mutation in other regions of Southeast
Asia [4,5,10] was detected in 1.6% of these samples. This
mutation was found to be significantly associated with
prolonged parasite clearance half-life in parasites from
Cambodia [5] and was confirmed to confer ART resist-
ance by genetic manipulations [7,8]. Most of the muta-
tions in the kelch domain, including the most prevalent
F446I mutation, remain to be genetically characterized
to determine whether they confer ART resistance.
Another intriguing phenomenon discovered in this
study is the highly prevalent microsatellite variations in
the N-terminus of the K13 gene. Compared to the wild-
type parasite, which has six N residues, 69.1% parasites
harboured eight N residues. The eight N variation was
only reported in Senegalese isolates with a frequency of
6.3% [16]. More interestingly, the predominant mutation
F446I was observed only in parasites with eight N re-
peats. In an earlier study, microsatellite variations in the
Wang et al. Malaria Journal  (2015) 14:168 Page 5 of 6nhe1 gene were associated with altered sensitivities to
quinine in parasite population from the same area [26].
Therefore, it would be interesting to find out whether
the K13 microsatellite variations affect parasites’ sensitiv-
ities to ART drugs.
ARTs have been used in the China-Myanmar border
area for over three decades, mostly as monotherapy
prior to 2005. The ACT drug deployed here is the dihy-
droartemisinin/piperaquine combination, compared to
artesunate/mefloquine in most other areas of the GMS.
One can hypothesize that it is likely that the distinct
K13 mutations observed in parasites from this study site
might have emerged separately as a result of selection
from a different ART regimen. In addition, given the pre-
dominant status of the C580Y mutation in other parts of
the GMS, it remains an open question as to whether the
presence of this mutation in these samples was due to in-
dependent emergence or had spread from other areas.
Furthermore, clinical efficacy studies also detected day-3
parasite positivity rate to >10% after artesunate treatment
of falciparum malaria in this area [32]. Taken together, in-
creased surveillance and population studies are needed to
determine further spread of ART resistance in the GMS.
Conclusions
Seventeen point mutations were identified in the K13
gene from 180 archived parasite samples collected from
the China-Myanmar border area. Analysis of the 191 para-
site strains identified 43.1% carrying point mutations in
the kelch domain, of which the F446I mutation reached a
predominance of 27.1%. Given the presence of K13 muta-
tions conferring ART resistance and detection of day-3
parasite positivity after ART drug treatment, increased
surveillance of P. falciparum for anti-malarial drug resist-
ance is highly demanded.
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